Achaogen

AKAO

11.51

-0.03

-0.3%

Please Login or Register

Login|Register FREE

Stock Price
Open: 11.89
Prev. Close: 11.54
Low/Hi: 11.39 - 11.89
52-Week: 10.24 - 27.79
Volumes
Equity: 427,813
90-Day Avg: 958,453
Option: 581
90-Day Avg: 605
Volatility
Todays Stock Vol: 59.3
20-Day (HV): 76.0
52-Week (HV): 66.6
30-Day IV: 67.8 -8.0
IV Pct Rank: 2% Subdued
Fundamental
Div. Yield:
Earnings: 15-Mar (Est.)
P/E Ratio:
Market Cap: 489.2 M
Short Int Pct: 0.0%
Pct Held By Inst.: 86.7%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

AKAO Company Events

Upcoming Events
Event Event Date Location Info
No Upcoming Events
Past Events
Event Event Date Location Info
Guggenheim Securities 5th Annual Boston Healthcare Conference Dec 13, 2017
Stifel 2017 Healthcare Conference Nov 14, 2017
IDWeek 2017 Oct 7, 2017
2017 Cantor Fitzgerald Global Healthcare Conference Sep 26, 4:35 PM
Wedbush PacGrow Healthcare Conference Aug 15, 10:55 AM
American Society for Microbiology (ASM) Microbe 2017 Annual Meeting Jun 1, 2017 - Jun 5, 2017
27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID). Apr 22, 2017 - Apr 25, 2017
Needham & Companys 16th Annual Healthcare Conference Apr 4, 10:40 AM
Cowen and Company 37th Annual Health Care Conference Mar 7, 2017
Treatment of Resistant Gram-Negative Infections Event Mar 1, 2017
Leerink Partners 6th Annual Global Healthcare Conference Feb 16, 2017
Management will review top-line plazomicin Phase 3 clinical results Dec 12, 8:30 AM
Stifel Healthcare Conference 2016 Nov 15, 2016 - Nov 16, 2016
Infectious Diseases Society of America (IDSA) IDWeek 2016 Oct 26, 2016 - Oct 30, 2016
i

Multiple data presentations from its plazomicin program.

Wedbush PacGrow Healthcare Conference Aug 17, 2016 Le Parker Meridien, New York, NY
Key Opinion Leader Meeting on Multi-Drug Resistant Infections Jul 19, 2016 New York City.
i

Members of the Achaogen executive management team will also provide an overview of and progress with the Companys ongoing clinical development program with lead product candidate, plazomicin, which is currently being evaluated in two Phase 3 clinical trials for the treatment of serious bacterial infections that include MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE.

ASM Microbe 2016 Annual Meeting Jun 16, 2016 - Jun 20, 2016
15th Annual Needham Health Care Conference Apr 12, 2016 Westin NY Grand Central Hotel, New York, NY
2015 Wedbush PacGrow Healthcare Conference Aug 12, 2015 Le Parker Meridien Hotel, New York, NY.
i

Kenneth Hillan, Chief Executive Officer, is scheduled to present

Annual Needham Healthcare Conference Apr 15, 2015
Bank of America Merrill Lynch 2015 Health Care Conference 4:40 PM
i

Dr. Kenneth Hillan, Chief Executive Officer, is scheduled to present

Cantor Fitzgerald Inaugural Healthcare Conference 11:45 AM
Credit Suisse Healthcare Conference

Wait, Before You Leave...

Want to Know More About AKAO Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon